Form 6-K Legend Biotech Corp For: Dec 31

Go back to Form 6-K Legend Biotech Corp For: Dec 31

JPMorgan on Legend Biotech Corp. (LEGN): 'Remain Confident in Carvykti’s Profile Post ODAC Briefing Docs'

March 13, 2024 12:10 PM EDT

JPMorgan analyst Jessica Fye reiterated an Overweight rating on Legend Biotech Corp. (NASDAQ: LEGN).

The analyst comments "While we expect the FDAs question around the imbalance in early death in CARTITUDE-4 to be taken seriously at Fridays ad com on Carvykti, the data around early deaths show it... More